Only in pancreatic cancer cells with high TLR-3 mRNA expression (CFPAC-1) does rintatolimod treatment reduces proliferation and migration rates….In conclusion, we propose that rintatolimod treatment might have a direct TLR-3-dependent anti-tumoral effect on pancreatic cancer cells expressing TLR-3....Altogether, our findings suggest that rintatolimod (Ampligen®) is a promising agent with the potential to induce cell growth arrest and reduce cell mobility in pancreatic cancer patients with sufficient tumor levels of TLR-3.